Brain-derived neurotrophic factor (BDNF) is a cognate ligand for the TrkB receptor. BDNF and serotonin often function in a cooperative manner to regulate neuronal plasticity, neurogenesis, and neuronal survival. Here we show that NAS (N-acetylserotonin) swiftly activates TrkB in a circadian manner and exhibits antidepressant effect in a TrkB-dependent manner. NAS, a precursor of melatonin, is acetylated from serotonin by AANAT (arylalkylamine Nacetyltransferase). NAS rapidly activates TrkB, but not TrkA or TrkC, in a neurotrophin-and MT3 receptor-independent manner. Administration of NAS activates TrkB in BDNF knockout mice. Furthermore, NAS, but not melatonin, displays a robust antidepressant-like behavioral effect in a TrkB-dependent way. Endogenous TrkB is activated in wild-type C3H/f +/+ mice but not in AANAT-mutated C57BL/ 6J mice, in a circadian rhythm; TrkB activation is high at night in the dark and low during the day. Hence, our findings support that NAS is more than a melatonin precursor, and that it can potently activate TrkB receptor.
B
rain-derived neurotrophic factor (BDNF) is a member of the neurotrophin family, which includes nerve growth factor, NT-3, NT-4, and NT-5 (1) . BDNF binding to TrkB triggers its dimerization through conformational changes and autophosphorylation of tyrosine residues in its intracellular domain, leading to activation of the three major downstream signaling cascades including mitogen-activated protein kinase (MAPK), phosphatidylinositol 3-kinase, and phospholipase C-γ1 (2, 3) . Through these pathways, BDNF mediates a variety of neuronal activities involved in neuronal survival, neurogenesis, synaptic plasticity, and so forth, and is implicated in numerous neurological diseases. For instance, loss of BDNF plays a major role in the pathophysiology of depression, and its restoration that induces neuroplastic changes may underlie the action of antidepressant efficacy (4) (5) (6) (7) .
Daily rhythms in indole metabolism are a unique characteristic of the pineal gland. Pineal serotonin (5-HT) levels are higher during the day than at night. Conversely, pineal N-acetylserotonin (NAS) and melatonin levels are low during the day and high at night (8) . The switch between day and night profiles of pineal indoles is predominantly regulated by the activity of arylalkylamine N-acetyltransferase (AANAT), which escalates at night 10-to 100-fold (9) . AANAT metabolizes serotonin into NAS. AANAT mRNA is prominently expressed in the pineal gland and retina, and weakly in other regions of brain (10) (11) (12) . NAS is mainly synthesized in the pineal gland, and is subsequently methylated by hydroxyindole-O-methyltransferase to synthesize melatonin. Until recently, NAS was considered only as the precursor of melatonin in the process of melatonin biosynthesis from serotonin. Melatonin is highly lipophilic and is not stored at significant levels. Accordingly, it is released into the blood immediately upon synthesis. Melatonin's role in the regulation of circadian rhythms and other functions is mediated primarily by membrane G-protein-coupled melatonin receptors (GPCRs): the MT1 and MT2 receptors. The MT3 binding site, a low-affinity melatonin receptor, is not a GPCR and represents a binding site in quinone reductase 2 (13) . Although melatonin is a potent, full agonist of MT1 and MT2 receptors, the MT3 binding site has a higher affinity for NAS than for melatonin. Thus, MT3 may act as an NAS receptor. NAS is widely distributed within the brainstem, cerebellum, and hippocampus, and in the brainstem it is contained within the reticular formation nuclei and motor nuclei (14) . NAS resides in the specific brain areas separate from melatonin and serotonin, suggesting that NAS may have a role in the central nervous system distinct from that of being a precursor for melatonin. In this report, we show that NAS but not serotonin or melatonin robustly activates TrkB in a neurotrophinand MT3-independent manner. Endogenous TrkB in retina and hippocampus is activated in wild-type C3H/f +/+ mice but not in AANAT-mutated C57BL/6J mice in a circadian rhythm. NAS displays robust antidepressant and neuroprotective effect in a TrkB-dependent manner.
Results

NAS, but Not Other Serotonin Metabolites, Induces TrkB Activation in
Primary Neurons. BDNF and serotonin often function in a cooperative manner to regulate neuronal plasticity and survival, indicating potential crosstalk between these two pathways. To explore whether serotonin metabolites can mediate TrkB activation, we treated hippocampal neurons with 100 nM 5-HT, 5-HIAA, NAS, or melatonin for 30 min. Immunoblotting showed that TrkB, but not TrkA, was activated by NAS, whereas 5-HT, 5-hydroxyindoleacetic acid (5-HIAA), and melatonin did not affect either receptor at this concentration (Fig. 1A) , which was also confirmed by immunofluorescent staining (Fig. S1 ). The activation of the downstream signaling proteins Akt and MAPK conformed to TrkB phosphorylation. Pretreatment with K252a, an inhibitor of the Trk receptors, diminished both BDNF-and NAS-triggered TrkB phosphorylation (Fig. 1B) , indicating that the stimulatory effect by NAS corresponds to Trk receptor-dependent autophosphorylation. NAS stimulated TrkB activation in a dose-dependent manner, and marked TrkB phosphorylation occurred at concentrations as low as 50 nM (Fig.  1C) . TrkB activation by NAS was detectable as early as 10 min, increased at 15 min, peaked at 30 min, and was sustained until 60 min, a kinetic pattern reminiscent of BDNF (Fig. 1D) . Hence, these data demonstrate that NAS, but not serotonin, 5-HIAA, or melatonin, provokes rapid TrkB activation in primary cortical neurons. As expected, NAS prevents glutamate-provoked apoptosis in primary neurons in a dose-dependent manner (Fig. S2 ).
Author contributions: S.-W.J. and K.Y. designed research; S.-W.J., X.L., S.P., G.T., and P.M.I. performed research; Q.C. contributed new reagents and analytical tools; P.M.I. and K.Y. analyzed data; and S.-W.J., P.M.I., and K.Y. wrote the paper.
The authors declare no conflict of interest.
*This Direct Submission article had a prearranged editor.
1
To whom correspondence should be addressed. E-mail: kye@emory.edu.
This article contains supporting information online at www.pnas.org/cgi/content/full/ 0912531107/DCSupplemental.
NAS Selectively Activates TrkB Independent of BDNF or MT3 Receptor.
Antidepressants increase hippocampal BDNF expression through enhanced 5-HT or norepinephrine (NE) neurotransmission (15) (16) (17) (18) . We reasoned that if NAS activates TrkB signaling indirectly by promoting BDNF secretion, scavenging BDNF should attenuate NAS-mediated activation of TrkB. To test this possibility, we pretreated primary cortical neurons with a neutralizing antibody to BDNF (BDNF-IgG) for 30 min, then added BDNF (50 ng/mL), NAS (100 nM), or serotonin (100 nM) for 15 min. Preincubation with BDNF-IgG abolished BDNF-induced phosphorylation of TrkB, but had no effect on NAS-induced TrkB phosphorylation. As expected, serotonin had no effect regardless of control IgG or BDNF antibody ( Fig. 2A) . To further exclude the possibility that NAS activated TrkB signaling indirectly mediated by BDNF, we prepared postnatal BDNF −/− cortical neurons from the offspring of BDNF +/− x BDNF +/− mice. BDNF and NAS exhibited similar levels of TrkB activation, whereas other serotonin metabolites had no effect (Fig. 2B) . Pretreatment with anti-NT-3 or anti-NT-4 antibody or their combination had no effect on TrkB activation by NAS in cortical neurons (Fig. 2C) . Hence, NAS activates TrkB receptor independent of neurotrophins.
NAS, 5-methoxycarbonylamino-N-acetyltryptamine (5-MCA-NAT), prazosin, and N-acetyltryptamine are ligands for the MT3 NAS binding site (19) . To determine whether the NAS-provoked TrkB activation is mediated by the MT3 binding site, we pretreated cortical neurons with various pharmacological agonists or antagonists of MT3 for 1 h, followed by the addition of 100 nM NAS. Blockade of the MT3 binding site failed to abrogate TrkB activation by NAS, and the MT3 agonist 5-MCA-NAT was unable to stimulate TrkB activation in the absence of NAS (Fig.  2D) , indicating that TrkB activation is not mediated by the canonical MT3 site. Recently, McNamara and colleagues demonstrated that zinc can transactivate TrkB by increasing Src family kinase activity via an activity-regulated mechanism independent of neurotrophins (20) . Here we show that zinc chelation inhibits the activation of TrkB by zinc, but not by NAS (Fig. S3) , which means NAS activates TrkB apart from zinc. Together, these data indicate that NAS triggers TrkB activation in a BDNF-and MT3-independent manner. NAS Specifically Activates the TrkB Receptor. To ask whether NAS can selectively activate the TrkB receptor, we prepared cortical neurons from pups of TrkB +/− mice which were mated to the same genotype. NAS but not serotonin specifically activated TrkB in wild-type but not TrkB-null neurons, whereas TrkA was not activated in neurons of either genotype (Fig. 3A) . Moreover, NAS strongly promoted TrkB but not TrkA activation in both wild-type and TrkC knockout neurons (Fig. 3B) . To further explore whether NAS can trigger TrkB activation in vivo, we employed TrkB F616A knockin mice, where it has been shown that TrkB F616A activation can be selectively blocked by 1NMPP1, a derivative of kinase inhibitor PP1, leading to TrkB-null phenotypes (21) . To assess whether NAS can mimic BDNF, we prepared cortical neurons from TrkB F616A knockin mice. In alignment with a previous report, BDNF-and NAS-mediated TrkB phosphorylation were selectively reduced by 1NMPP1 but not by K252a, whereas serotonin or melatonin had no effect (Fig. 3C ). These findings suggest that NAS strongly provokes both wild-type TrkB and TrkB F616A tyrosine phosphorylation and activation.
Because 1NMPP1 selectively inhibits TrkB F616A activation by NAS, we hypothesized that blockade of TrkB F616A signaling by 1NMPP1 in mice would make the neurons vulnerable to kainic acid (KA) -provoked neuronal cell death. We pretreated F616A mice with 1NMPP1, followed by administration of NAS or melatonin. After 1 h, the mice were injected with KA. Treatment with 1NMPP1 or NAS alone or 1NMPP1 + NAS together had no effect on caspase 3 activation in TrkB F616A mice. KA caused marked caspase 3 activation, and pretreatment of 1NMPP1 elevated KA-mediated apoptosis in TrkB F616A, indicative of the critical role of TrkB signaling for neuronal survival (Fig. 3D) . NAS markedly suppressed KA-provoked caspase 3 activation, whereas 1NMPP1 pretreatment greatly diminished NAS's protective effect in F616A mice. NAS induced robust TrkB activation in TrkB F616A mice, and pretreatment with 1NMPP1 markedly diminished TrkB activation. By contrast, melatonin had no effect regardless of 1NMPP1. TrkB activation status was inversely correlated with TrkB activation by NAS (Fig.  3D ). BDNF levels were not affected by treatment with NAS or melatonin, suggesting that BDNF is not involved in the TrkB stimulatory effect by NAS. Therefore, NAS can selectively promote TrkB activation in mice.
TrkB Receptor in Retina and Hippocampus Is Activated in Wild-Type C3H/f +/+ Mice but Not in AANAT-Mutated C57BL/6J Mice in a Circadian
Pattern. BDNF and its receptor TrkB play an important role in the neuroprotection of retinal ganglion cells, which express both BDNF and its receptor TrkB (22) . To explore whether NAS could activate endogenous TrkB in the absence of BDNF, BDNF forebrain conditional knockout mice, which lack cortical, hippocampal, and retinal BDNF, were injected intraperitoneally with NAS or melatonin. We found that both hippocampal and retinal TrkB phosphorylation was evident after 0.5 h and peaked 1 h following NAS administration. In contrast, melatonin had no effect (Fig. 4A ). These findings indicate that NAS provokes TrkB activation independent of BDNF in vivo. Pineal NAS and melatonin levels fluctuate with circadian rhythms, with low levels during the day and high levels at night (8) . If NAS acts as an endogenous TrkB agonist, TrkB activation pattern should correlate with NAS oscillation. We next determined TrkB activation at different times of day in retinas of C3H/f +/+ mice kept in constant darkness for 3 days. Whereas TrkB phosphorylation was not detectable at 0 h (subjective morning), TrkB was evidently activated at 6 h, peaked at 12 h, and decreased slightly at 18 h. Total TrkB levels remained similar in all mice (Fig. 4B ). This finding suggests that endogenous TrkB activation oscillates in a circadian rhythm, with high activity during the subjective night and low activity during the subjective morning.
C3H/f +/+ mice express wild-type AANAT, whereas C57BL/6J mice have a mutant AANAT gene and are considered AANATdeficient (10) (11) (12) . If NAS is indeed an endogenous agonist for TrkB in vivo, then the circadian rhythm of TrkB activation would be expected to be abolished in C57BL/6J mice as compared to C3H/f +/+ mice. We prepared the hippocampal tissues and retina from both C57BL/6J and C3H/HeJ mice at 2 and 14 h, respectively. As predicted, in wild-type C3H/f +/+ mice, TrkB was robustly activated in retinal and hippocampal tissues at 14 h, whereas negligible TrkB phosphorylation occurred at 2 h in both tissues. By contrast, no significant TrkB activation was detected in either tissue in C57BL/6J mice (Fig. 4C) . Together, these results indicate that NAS can selectively activate hippocampal and retinal TrkB in a circadian-clock-controlled manner. (24) . To explore whether NAS is implicated in triggering TrkB activation by antidepressant drugs in animals, we injected AANATimpaired C57BL/6J mice with a variety of antidepressants and monitored TrkB activation. The selective serotonin reuptake inhibitors fluoxetine and citalopram, and tricyclic antidepressant desipramine, robustly stimulated TrkB activation in hippocampus of mice exposed to light or darkness, whereas MAO inhibitors had little effect (Fig. 5A) . A similar response to specific serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants was observed in C3H/f +/+ mice (Fig. 5B) . Interestingly, in C3H mice treated at night, clorgyline strongly activated TrkB in the dark; in contrast, it lost the stimulatory effect in light-exposed mice, suggesting that clorgyline-triggered NAS is attributable to this effect in darkness. Because deprenyl does not stimulate NAS levels, it was unable to trigger TrkB activation no matter whether the light was on or off. However, the SSRIs and tricyclic antidepressant markedly activated TrkB regardless of dark or light. This result combined with the observation that these drugs stimulate TrkB phosphorylation in hippocampus of C57BL/6J mice with defective AANAT indicates that NAS is not a major effector in TrkB activation by these agents (Fig. 5B Left) . Clorgyline increases both melatonin and NAS levels in rat pineal glands (24) . To explore which of the 5-HT metabolites possesses antidepressant-like behavioral activity, we conducted a forced-swim experiment with NAS-deficient C57BL/6J mice. NAS (20 mg/kg), which was administrated intraperitoneally 1 h before testing, significantly decreased the duration of immobility as compared to saline control. By contrast, melatonin (1 mg/kg) had little effect (Fig. 5C Left) . This finding is consistent with a previous report that NAS reduces duration of immobility in a dose-dependent manner in the tail-suspension test, whereas melatonin at 1 mg/kg did not affect duration of immobility (25) . Notably, NAS also strongly reduced the immobility in TrkB F616A mice; by contrast, 1NMPP1 pretreatment abolished the antidepressant-like behavioral effect by NAS, indicating that its antidepressant effect is mediated through TrkB (Fig. 5C Right) .
Discussion
In this report, we show that NAS robustly activates TrkB receptor and reveal potent antidepressant and neuroprotective effects of a TrkB-dependent manner. We present several lines of evidence demonstrating that NAS promotes TrkB activation in a neurotrophin-and MT3 NAS receptor-independent manner. How does NAS activate TrkB receptor? One possibility is that NAS directly binds TrkB receptor and acts as an agonist. To explore this notion, we have conducted extensive ligand/receptor binding assays. Nonetheless, in vitro ligand binding assays with purified TrkB receptor proteins or transfected cell membrane and [ 3 H]NAS vary, which is presumably due to rapid ligand association/dissociation kinetics. To optimize stable binding conditions, it is necessary to ascertain whether NAS indeed functions as an endogenous TrkB receptor agonist. Because NAS has a short halflife, synthesizing a more stable derivative might provide a more robust agonistic effect on TrkB receptor, which may be clinically useful for treating various neurological diseases.
Administration of NAS but not melatonin causes TrkB activation in mice lacking BDNF. More strikingly, we show potent TrkB activation in wild-type C3H/f +/+ mice in a circadian pattern, which temporally fits the NAS oscillation, and this effect is absent in AANAT-mutated C57BL/6J mice. Moreover, NAS but not melatonin possesses a robust antidepressant-like behavioral effect, which is TrkB-dependent. Selective MAO-A inhibitors stimulate the production of NAS and melatonin in the pineal gland, suggesting that the serotonin metabolites contribute to the clinical antidepressant effect of MAO-A inhibitors (26) . However, melatonin does not display any antidepressant-like effect in the forced-swim test in Wistar rats or in C3H mice (27) . On the other hand, C57BL/6J mice displayed significantly longer times of immobility ("depression") in the forced-swim test than C3H mice (28) , suggesting that endogenous NAS might have an antidepressant effect. Further, the finding that TrkB activation by clorgyline in C3H but not C57BL/6J mice is prevented by light exposure, which inhibits NAS synthesis, suggests that endogenous NAS induced by clorgyline accounts for this effect.
It has been proposed that NAS could be a mediator of the antidepressant action of drugs, and chronic but not acute treatment of rats with the antidepressant fluoxetine increases the content of AANAT mRNA in the rat hippocampus (29) . Moreover, in a tail-suspension test, a significantly longer immobility time in C57BL/6J than in C3H mice was reported as well (28, 30) . Our finding that NAS activates TrkB provides a molecular mechanism explaining the antidepressant role of NAS (Fig. 5) . Conceivably, chronic fluoxetine treatment up-regulates AANAT and increases the abundance of NAS, which in turn activates TrkB, leading to escalation in synaptic plasticity, neurogenesis, and synaptogenesis (31) . A growing body of evidence suggests that BDNF-mediated TrkB signaling is both sufficient and necessary for antidepressant-like behaviors in rodents. It is possible that NAS and BDNF might additively or synergistically regulate each other's neurotrophic activity on TrkB.
NAS has different brain distribution patterns from those of serotonin and melatonin. Similarly, primate retina expresses AANAT but not hydroxyindole-O-methyltransferase, the enzyme that converts NAS to melatonin (32) . These findings suggest that NAS might have functions other than as a precursor or metabolite of melatonin. If this hypothesis is true, it would suggest that indoleamines have certain similarities to catecholamines. Thus, for the catecholamines, dopamine, norepinephrine, and epinephrine form a synthetic sequence and yet have independent roles as neurotransmitters and/or hormones. The three indoleamines serotonin, NAS, and melatonin also form a synthetic sequence, and these three substances may also have independent roles as neurotransmitters and/or hormones (14) . In the current study, we provide a large amount of evidence that supports that NAS, like BDNF, robustly activates TrkB receptor. The neurotrophic activity can readily explain the physiological effects of NAS, including neuroprotective, cognition-enhancing, antiaging, and antidepressant (25) actions, because TrkB signaling is essential for these activities. Taken together, our data show that NAS is more than just a precursor of melatonin; it strongly exerts antidepressant and neuroprotective effects through TrkB receptor.
Materials and Methods
Cells, Reagents, and Mice. HEK293 cells were maintained in medium A (DMEM with 10% fetal bovine serum and 100 units of penicillin-streptomycin) and cultured at 37°C in a 5% CO 2 atmosphere in a humidified incubator. BDNF was from Peptron. Phospho-Akt-473 or -308, pan-Akt, anti-phospho-Erk1/2, and anti-phospho-TrkA Y490 antibodies were from Cell Signaling. TrkA antibody was from Santa Cruz Biotechnology. Anti-p-TrkA 794 has been described previously (33) . Anti-TrkB antibody was from BioVision. Anti-pTrkB 816 has been described previously (34 , and deprenyl (2 mg/kg) were injected i.p. into C57BL/6J or C3H/f +/+ mice just before the onset of darkness of the light-dark cycle. Mice were kept in darkness or light and killed after 1-2 h. Brain lysates were prepared and analyzed by immunoblotting. Analysis was by one-way ANOVA, followed by Dunnett's test. Differences were considered significant if P < 0.05 (*P < 0.01 against saline; **, not significant; n = 3/group). (C) NAS exerts its antidepressant effect in a TrkB-dependent manner. Forced-swim test. Two-to three-month-old C57BL/6J male mice (n = 8 mice/ group) were treated with NAS (20 mg/kg), melatonin (1 mg/ kg), or vehicle by i.p. injection. After 1 h, the mice were subjected to a forced-swim test (6 min; immobility was recorded in the last 4 min; left panel). Forced-swim test with TrkB F616A knockin mice. Male TrkB knockin mice were given regular drinking water or 1NMPP1-containing drinking water 2 days before NAS administration. Data are presented as mean ± SEM; one-way ANOVA, followed by Dunnett's test; if significant, P < 0.05 (#, not significant; ***P < 0.0001 against saline group; left panel) (*P < 0.001 against control vehicle, right panel).
8-week-old Bdnf 2/2 ;cre93 mice. Mice were killed 30 min, 1 h, or 2 h after either NAS or melatonin injection. Retina and hippocampi were dissected quickly and snap-frozen in liquid nitrogen.
Treatment of Mice with NAS and Melatonin. Two-month-old TrkB F616A mice were pretreated with 1NMPP1 in drinking water (50 μM) 1 day before the experiment, followed by administration of NAS (20 mg/kg, i.p.) or melatonin (1 mg/kg, i.p.). Mice were killed at 1 h. The brain homogenates were analyzed by immunoblotting with anti-p-TrkB. Two-to three-month-old BDNF forebrain conditional knockout mice were injected i.p. with NAS or melatonin. Mice were killed at 0, 0.5, 1, or 2 h following drug administration. Brain lysates were prepared and analyzed by immunoblotting with antiphospho-TrkB Y816.
Antidepressant Treatment with C3H and C57BL/6J Mice. Mice were injected intraperitoneally with saline, fluoxetine (30 mg/kg), citalopram (20 mg/kg), desipramine (20 mg/kg), clorgyline (2 mg/kg), and deprenyl (2 mg/kg) immediately before the normal time of dark onset of the 12-h light/12-h dark cycle. One half of the mice were kept in darkness while the other mice were exposed to light. Mice were killed 1-2 h after injection and hippocampi were dissected and frozen. Euthanasia of mice in darkness was done under dim red light.
Forced-Swim Test. Adult male mice (2-3 months old) were randomly submitted to a forced-swim test without a preswim. Saline, N-acetylserotonin (20 mg/kg), and melatonin (1 mg/kg) were i.p. injected 1 h before the experiment. The mice were placed in a clear glass cylinder with a diameter of 16 cm, half-filled with clear water at 24°C (water depth of 14 cm did not allow the mice to reach the bottom of the cylinder; water was changed after each mouse) for a total of 6 min, and immobility was recorded during the last 4 min by an investigator blind to the genotype and treatment.
